BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sacco MD, Hu Y, Gongora MV, Meilleur F, Kemp MT, Zhang X, Wang J, Chen Y. The P132H mutation in the main protease of Omicron SARS-CoV-2 decreases thermal stability without compromising catalysis or small-molecule drug inhibition. Cell Res 2022. [PMID: 35292745 DOI: 10.1038/s41422-022-00640-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 26.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen W, Shao Y, Peng X, Liang B, Xu J, Xing D. Review of preclinical data of PF-07304814 and its active metabolite derivatives against SARS-CoV-2 infection. Front Pharmacol 2022;13. [DOI: 10.3389/fphar.2022.1035969] [Reference Citation Analysis]
2 Brady DK, Gurijala AR, Huang L, Hussain AA, Lingan AL, Pembridge OG, Ratangee BA, Sealy TT, Vallone KT, Clements TP. A guide to COVID ‐19 antiviral therapeutics: a summary and perspective of the antiviral weapons against SARS‐CoV ‐2 infection. The FEBS Journal 2022. [DOI: 10.1111/febs.16662] [Reference Citation Analysis]
3 Sasi VM, Ullrich S, Ton J, Fry SE, Johansen-leete J, Payne RJ, Nitsche C, Jackson CJ. Predicting Antiviral Resistance Mutations in SARS-CoV-2 Main Protease with Computational and Experimental Screening. Biochemistry 2022. [DOI: 10.1021/acs.biochem.2c00489] [Reference Citation Analysis]
4 Nguyenla X, Wehri E, Van Dis E, Biering SB, Yamashiro LH, Zhu C, Stroumza J, Dugast-Darzacq C, Graham TGW, Wang X, Jockusch S, Tao C, Chien M, Xie W, Patel DJ, Meyer C, Garzia A, Tuschl T, Russo JJ, Ju J, Näär AM, Stanley S, Schaletzky J. Discovery of SARS-CoV-2 antiviral synergy between remdesivir and approved drugs in human lung cells. Sci Rep 2022;12:18506. [PMID: 36323770 DOI: 10.1038/s41598-022-21034-5] [Reference Citation Analysis]
5 Patel CN, Jani SP, Sivakumar PK, Modi KM, Kumar Y. Computational investigation of natural compounds as potential main protease (Mpro) inhibitors for SARS-CoV-2 virus. Computers in Biology and Medicine 2022. [DOI: 10.1016/j.compbiomed.2022.106318] [Reference Citation Analysis]
6 Desmarets L, Callens N, Hoffmann E, Danneels A, Lavie M, Couturier C, Dubuisson J, Belouzard S, Rouillé Y. A reporter cell line for the automated quantification of SARS-CoV-2 infection in living cells. Front Microbiol 2022;13:1031204. [DOI: 10.3389/fmicb.2022.1031204] [Reference Citation Analysis]
7 Ma L, Li Q, Xie Y, Jianyuan Zhao, Yi D, Guo S, Guo F, Wang J, Yang L, Cen S. Repurposing of HIV/HCV protease inhibitors against SARS-CoV-2 3CLpro. Antiviral Res 2022;:105419. [PMID: 36155070 DOI: 10.1016/j.antiviral.2022.105419] [Reference Citation Analysis]
8 Parigger L, Krassnigg A, Schopper T, Singh A, Tappler K, Köchl K, Hetmann M, Gruber K, Steinkellner G, Gruber CC. Changes in the mutational dynamics of the SARS-CoV-2 main-protease substantiate the danger of emerging resistance to antiviral drugs.. [DOI: 10.21203/rs.3.rs-1858067/v2] [Reference Citation Analysis]
9 Hu Y, Lewandowski EM, Tan H, Zhang X, Morgan RT, Zhang X, Jacobs LMC, Butler SG, Gongora MV, Choy J, Deng X, Chen Y, Wang J. Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir. bioRxiv 2022:2022. [PMID: 36119652 DOI: 10.1101/2022.06.28.497978] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
10 Wang T, Cao Y, Zhang H, Wang Z, Man CH, Yang Y, Chen L, Xu S, Yan X, Zheng Q, Wang YP. COVID-19 metabolism: Mechanisms and therapeutic targets. MedComm (2020) 2022;3:e157. [PMID: 35958432 DOI: 10.1002/mco2.157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Sasi VM, Ullrich S, Ton J, Fry SE, Johansen-leete J, Payne RJ, Nitsche C, Jackson CJ. Predicting antiviral resistance mutations in SARS-CoV-2 main protease with computational and experimental screening.. [DOI: 10.1101/2022.08.24.505060] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Wang Z, Belecciu T, Eaves J, Reimers M, Bachmann MH, Woldring D. Phytochemical drug discovery for COVID-19 using high-resolution computational docking and machine learning assisted binder prediction. J Biomol Struct Dyn 2022;:1-21. [PMID: 35993534 DOI: 10.1080/07391102.2022.2112976] [Reference Citation Analysis]
13 Ferrara F, Zovi A, Trama U, Vitiello A. Nirmatrelvir-remdesivir association for non-hospitalized adults with COVID-19, point of view. Inflammopharmacology 2022. [PMID: 35980509 DOI: 10.1007/s10787-022-01055-2] [Reference Citation Analysis]
14 Gruber C, Parigger L, Krassnigg A, Schopper T, Singh A, Tappler K, Köchl K, Hetmann M, Gruber K, Steinkellner G. Recent changes in the mutational dynamics of the SARS-CoV-2 main-protease substantiate the danger of emerging resistance to antiviral drugs.. [DOI: 10.21203/rs.3.rs-1858067/v1] [Reference Citation Analysis]
15 Ou J, Lewandowski EM, Hu Y, Lipinski AA, Morgan RT, Jacobs LM, Zhang X, Bikowitz MJ, Langlais P, Tan H, Wang J, Chen Y, Choy JS. A yeast-based system to study SARS-CoV-2 Mpro structure and to identify nirmatrelvir resistant mutations.. [DOI: 10.1101/2022.08.06.503039] [Reference Citation Analysis]
16 de Oliveira VM, Ibrahim MF, Sun X, Hilgenfeld R, Shen J. H172Y mutation perturbs the S1 pocket and nirmatrelvir binding of SARS-CoV-2 main protease through a nonnative hydrogen bond.. [DOI: 10.1101/2022.07.31.502215] [Reference Citation Analysis]
17 Kashyap P, Bhardwaj VK, Chauhan M, Chauhan V, Kumar A, Purohit R, Kumar A, Kumar S. A ricin-based peptide BRIP from Hordeum vulgare inhibits Mpro of SARS-CoV-2. Sci Rep 2022;12:12802. [PMID: 35896605 DOI: 10.1038/s41598-022-15977-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Mahmanzar M, Houseini ST, Rahimian K, Namini AM, Gholamzad A, Tokhanbigli S, Sisakht MM, Farhadi A, Kuehu DL, Deng Y. The First Geographic Identification by Country of Sustainable Mutations of SARS-COV2 Sequence Samples: Worldwide Natural Selection Trends.. [DOI: 10.1101/2022.07.18.500565] [Reference Citation Analysis]
19 Yan H, Liu Z, Yan G, Liu X, Liu X, Wang Y, Chen Y. A robust high-throughput fluorescence polarization assay for rapid screening of SARS-CoV-2 papain-like protease inhibitors. Virology 2022;574:18-24. [PMID: 35870326 DOI: 10.1016/j.virol.2022.07.006] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Sun C, Xie C, Bu GL, Zhong LY, Zeng MS. Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants. Signal Transduct Target Ther 2022;7:202. [PMID: 35764603 DOI: 10.1038/s41392-022-01039-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
21 Yang KS, Leeuwon SZ, Xu S, Liu WR. Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir. J Med Chem 2022. [PMID: 35731933 DOI: 10.1021/acs.jmedchem.2c00404] [Cited by in Crossref: 8] [Cited by in F6Publishing: 17] [Article Influence: 8.0] [Reference Citation Analysis]
22 Sedova M, Jaroszewski L, Iyer M, Godzik A. Monitoring for SARS-CoV-2 drug resistance mutations in broad viral populations.. [DOI: 10.1101/2022.05.27.493798] [Reference Citation Analysis]
23 Tan H, Hu Y, Jadhav P, Tan B, Wang J. Progress and Challenges in Targeting the SARS-CoV-2 Papain-like Protease. J Med Chem 2022. [PMID: 35620927 DOI: 10.1021/acs.jmedchem.2c00303] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
24 Li D, Yan G, Zhou W, Si S, Liu X, Zhang J, Li Y, Chen Y. Ginkgolic acid and anacardic acid are reversible inhibitors of SARS-CoV-2 3-chymotrypsin-like protease. Cell Biosci 2022;12:65. [PMID: 35590420 DOI: 10.1186/s13578-022-00806-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Ramos-Guzmán CA, Velázquez-Libera JL, Ruiz-Pernía JJ, Tuñón I. Testing Affordable Strategies for the Computational Study of Reactivity in Cysteine Proteases: The Case of SARS-CoV-2 3CL Protease Inhibition. J Chem Theory Comput 2022. [PMID: 35549334 DOI: 10.1021/acs.jctc.2c00294] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]